Pipeline

Pipeline

The Potential to
Transform Treatment

Anokion is on the leading edge of harnessing the body’s natural immune tolerance pathway to address significant unmet medical need. Our innovative platform has the potential to treat multiple autoimmune diseases with therapies that deliver substantial clinical benefit without the untoward side effects associated with the current standard of care. Our goal is to discover, develop and deliver transformative therapies by directly and specifically modulating the patient’s own disease-associated T cells.

Discovery
IND-Enabling
Phase 1/2
Celiac Disease

KAN-101
Phase 1 Complete

KAN-101
 
Multiple Sclerosis

ANK-700
Phase 1

ANK-700
 
Type 1 Diabetes

KAN-201
Candidate Selected

KAN-201
 
Undisclosed

Candidate Selection